Medtronic PLC $MDT Shares Bought by Commerzbank Aktiengesellschaft FI

Commerzbank Aktiengesellschaft FI raised its stake in shares of Medtronic PLC (NYSE:MDT) by 33.4% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 39,167 shares of the medical technology company’s stock after acquiring an additional 9,811 shares during the period. Commerzbank Aktiengesellschaft FI’s holdings in Medtronic were worth $3,731,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently modified their holdings of the stock. Brighton Jones LLC raised its position in Medtronic by 1,368.0% during the fourth quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock valued at $3,194,000 after acquiring an additional 37,265 shares in the last quarter. Sivia Capital Partners LLC grew its stake in shares of Medtronic by 9.6% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company’s stock worth $380,000 after purchasing an additional 381 shares during the period. Perigon Wealth Management LLC increased its holdings in shares of Medtronic by 8.0% during the 2nd quarter. Perigon Wealth Management LLC now owns 14,831 shares of the medical technology company’s stock valued at $1,293,000 after purchasing an additional 1,096 shares in the last quarter. Kathmere Capital Management LLC lifted its stake in shares of Medtronic by 29.9% in the 2nd quarter. Kathmere Capital Management LLC now owns 7,772 shares of the medical technology company’s stock valued at $677,000 after purchasing an additional 1,788 shares during the period. Finally, Cove Private Wealth LLC lifted its stake in shares of Medtronic by 11.0% in the 2nd quarter. Cove Private Wealth LLC now owns 16,629 shares of the medical technology company’s stock valued at $1,450,000 after purchasing an additional 1,650 shares during the period. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Analyst Upgrades and Downgrades

MDT has been the topic of several analyst reports. Morgan Stanley raised their price target on shares of Medtronic from $107.00 to $117.00 and gave the company an “overweight” rating in a research report on Wednesday, November 19th. Piper Sandler restated a “neutral” rating on shares of Medtronic in a research report on Monday, January 5th. William Blair raised Medtronic from a “market perform” rating to an “outperform” rating in a report on Tuesday, January 6th. Barclays increased their price target on Medtronic from $111.00 to $116.00 and gave the stock an “overweight” rating in a research report on Thursday, January 8th. Finally, Wall Street Zen upgraded Medtronic from a “hold” rating to a “buy” rating in a research report on Friday. Fourteen analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $110.28.

Medtronic Trading Down 0.4%

MDT stock opened at $100.98 on Friday. Medtronic PLC has a 12-month low of $79.55 and a 12-month high of $106.33. The business’s 50-day moving average is $99.44 and its 200 day moving average is $95.28. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57. The stock has a market cap of $129.45 billion, a price-to-earnings ratio of 27.22, a PEG ratio of 2.66 and a beta of 0.71.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, beating analysts’ consensus estimates of $1.31 by $0.05. The business had revenue of $8.96 billion during the quarter, compared to analysts’ expectations of $8.86 billion. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The business’s revenue was up 6.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.26 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, sell-side analysts anticipate that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, January 16th. Shareholders of record on Friday, December 26th were paid a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend was Friday, December 26th. Medtronic’s payout ratio is 76.55%.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).